On Apr. 27, 2020, RedHill Biopharma provided an additional update on the compassionate use program with its investigational drug, opaganib (Yeliva, ABC294640)1, in patients with confirmed SARS-CoV-2 infection in Israel.

Preliminary findings from all six patients analyzed had shown that all the patients demonstrated objective significant measurable clinical improvement within days following treatment initiation with opaganib.